While several HDACi are approved by the FDA as a single agent in the treatment of different type of cancers, combination of HDACi with chemotherapeutic agents, epigenetic regulators such as demethylating agents or Bet inhibitors may increase their therapeutic potential. Here, DNER is linked to cancer.